Olema Oncology to Present at the TD Cowen 45th Annual Health Care Conference

Core Insights - Olema Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on targeted therapies for breast cancer and other conditions [1][3] - The company will present at the TD Cowen 45 Annual Health Care Conference on March 5, 2025 [1] - Olema's lead product candidate, palazestrant (OP-1250), is currently in a Phase 3 clinical trial called OPERA-01 [3] Company Overview - Olema Oncology is dedicated to transforming the standard of care for patients with breast cancer [3] - The company is advancing a pipeline of novel therapies by leveraging expertise in endocrine-driven cancers and mechanisms of acquired resistance [3] - Olema is headquartered in San Francisco, California, with operations in Cambridge, Massachusetts [3]